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Vernonia amygdalina is commonly used for food and health purposes. The processing 
of the leaf for food is usually aimed at removing bitter tasting principles like saponins. 
This study was designed to determine the antipyretic and antinociceptive properties of 
the aqueous extract, crude saponin and the chromatographic fraction of the crude 
saponin from the leaf. In the antipyretic evaluation, anal temperature change in fasted 
rats with prior induced pyrexia using intra-peritoneal administered 15% w/v 
Saccharomyces cerevisiae, was measured four hours after dose administration. In the 
antinociceptive evaluation, 0.6% acetic acid solution administered by intra peritoneal 
route at a dose of 15 ml/kg was used to induce writhing in the writhing test; hot plate 
at 55 °C ± 1 to induce thermal pain in the hot plate test; and cold mixture of water and 
ethylene glycol (1:1) maintained at -10 °C to initiate pain sensation in the cold tail 
flick tests. Antipyretic data showed significant (P ≤ 0.05) anal temperature decrease 
for all the test doses compared to the placebo. This was markedly observed with the 
aqueous extract at 0.55 oC ± 0.03 anal temperature decrease, compared to the 0.29 0C 
± 0.01 of the crude saponin, at a similar dose level of 400 mg/kg. At 200 mg/kg dose, 
the crude saponin induced an anal temperature decrease of 0.14 0C ± 0.02. This was 
higher than the response obtained with the chromatographic fraction which produced 
0.06 0C ± 0.01 anal temperature decrease. Antinociceptive data was significant (P ≤ 
0.05) for the crude saponin in the writhing (52.58 % antinociceptic effect) and hot 
plate tests (14.24 maximum percent analgesia), contrary to observation in the cold tail 
flick test. Findings showed the antipyretic and non-steroid like antinociceptive 
property of the crude saponin, which may support the rationale for the use of 
Vernonia amygdalina leaf to reduce fever and/or pain. 
 











Some vegetables commonly eaten as food have been shown to be beneficial in herbal 
therapy [1]. Vernonia amygdalina is a widely used local vegetable in Uganda, Nigeria 
and other African countries. It grows in a range of ecological zones in Africa and the 
Arabian Peninsula [2]. It is commonly referred to as “bitter leaf” and locally, 
“omubirizi” or “omululuza” (West and Central Uganda); “olusia” (Luo, Kenya); or 
“ewuro”, “etidot” and “olugbo” (Southern Nigeria). The leaf is used for both its 
nutritional and therapeutic benefits [3]. In Southern Ethiopia, dairy farmers feed the 
leaf to their stock during the dry period, after boiling to decrease the bitter taste. Prior 
study showed that feed intake, body weight gain and feed efficiency were not affected 
when the leaf was used to replace 300 g/ kg of maize-based diet fed to broilers [2]. 
 
Numerous phytochemicals have been shown to be present in the leaf extract of this 
plant [3]. The bitter taste of the leaf has been attributed to the presence of anti-
nutritive principles like saponins, alkaloids, tannins and glycosides [4]. Leaf 
processing for human consumption, which involves the soaking and washing in warm 
water tends to reduce these bitter tasting principles. 
 
Saponins are glycosides widely distributed in plants. They are characterized by the 
number of sugar chains attached to the triterpene or steroid aglycone backbone, also 
called sapogenin. While evidence has shown that the main dietary sources of saponins 
are the dicotyledon like legumes, the main non-food sources used in health and 
industrial applications include the soap bark tree, Medicago sativa, Aesculus 
hippocastanum and Glycyrrhiza glabra [5]. 
 
Saponins in foods have traditionally been considered bitter and unpleasant thereby 
limiting their use [3]. Most of the earlier studies on processing techniques targeted 
their removal to facilitate human consumption of the resulting product [6]. However, 
the food and non-food sources of saponins have come into renewed focus in recent 
years due to increasing evidence of their health benefits [7]. Recent evidence 
highlighted saponin contribution to the health benefit of some foodstuffs, and also as 
one of the active components in some herbal medicines [8, 9]. The major objective of 
this study was to investigate the antinociceptive and antipyretic properties of the 
aqueous extract, crude saponin and the chromatographic fraction of crude saponin 
(Va-SB: Vernonia amygdalina saponin fraction B) from Vernonia amygdalina leaf.  
 
MATERIALS AND METHODS 
 
Chemicals, Drugs and Test Agents: 
Analytical grades of methanol, n-butanol, diethyl ether, chloroform, acetone, and 
xylene from BDH, Uganda and acetic acid (Sigma-Aldrich, Germany) were used. 
Active dry Saccharomyces cerevisiae: brewer’s yeast (Griffchem®) was used to 
induce pyrexia in the antipyretic study. A dose of 300 mg/kg acetylsalicylic acid 
(ASA) (Pinewood, Caprin®) as reference standard, 5 ml/kg normal saline solution 
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saponin as test samples were used in all the experiments. Morphine sulphate (Ministry 
of Health Molago, Kampala) as opioid reference standard at a dose of 5 mg/kg was 
used in the antinociceptive study while Va-SB (V. amygdalina saponin fraction B), 
was used as one of the test samples in the antipyretic study. 
 
Plant Material and Extraction 
The fresh leaves of Vernonia amygdalina identified by a botanist were collected in the 
morning, between June and July (raining season) in south-western Uganda region.  
Specimens were retained with voucher number 16-20 in the Pharmacy Department, 
Faculty of Medicine, Mbarara University of Science and Technology. The leaves 
were shade air-dried and ground into a coarse powder that was sieved to 2000 g fine 
powder. The moistened powder was allowed to stand for 15 minutes before 
maceration for three hours in warm (<80 oC) distilled water at a modified ratio of 131 
g to 9.0 litres with intermittent shaking [10]. The obtained infusion was filtered 
through filter-paper while warm. The filtrate was further filtered using buckner filter 
assemblage (aided by a suction pump) and subsequently evaporated to dryness in an 
oven (at ≤ 80oC). The total amount of yield (leaf residue) obtained was 18 %. This 
was stored in a desiccator at room temperature (25 oC) until required for use. 
 
Phytochemical Screening 
Preliminary screening of the aqueous extract for phytochemicals was carried out using 
standard procedures [11]. Test procedures carried out were, foaming assay for 
saponins; dragendorff’s test for Alkaloids; baljet test for sophisticated lactones; 
liebermann-burchard test for triterpenes and steroids; fehling test for reducing sugars; 
ninhydrine test for amino acids; shinoda assay for flavonoids; borntragers test for 
quinines; salkowski test for terpenoids; ferric chloride test for tannins; and kedde’s 
assay for cardiotonic glycosides. 
 
Isolation and Fractionation of crude Saponin 
ISOLATION: The liquid-liquid extraction technique as described by Obadoni and 
Ochuko in 2001 [12] was adopted for the isolation. A forty millimetre solution was 
prepared in distilled water using 20 g of the dried aqueous extract of V. amygdalina 
leaf. This was extracted thrice with 20 ml diethyl ether.  The diethyl ether layer was 
discarded and the retained aqueous layer extracted further with 60 ml n-butan-1-ol 
(four times).  The n-butan-1-ol extracts were bulked together and washed four times 
using 10 ml of five percent NaCl. The washed extract was concentrated at < 80 0C in 
an oven and air dried at room temperature to yield 1.81 g (9.1 % w/w) of crude saponin 
residue. The residue was screened for saponin using the foaming test [11]. 
 
FLASH COLUMN CHROMATOGRAPHIC FRACTIONATION: The crude saponin 
dissolved in methanol was adsorbed onto a TLC grade silica gel (CSI 010, Unilab) at 
a ratio of two to five and dried in an oven at <800C to produce a 21 g free flowing 
powder. The powder was loaded and fractionated on a silica gel (May & Baker 
Dagenham, England: 0.2-0.5 mm, pore size 40 amgstrom, 30-70 mesh) containing 
flash column [13]. The column was eluted with a gradient mobile phase solvent 
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methanol (one to one); and methanol, in multiples of 100 ml. An air pump (Merck, 
Germany) was used to facilitate the rate of elution. Each 100ml effluent collected was 
profiled using TLC with a mobile phase system of acetone, chloroform and methanol 
(at a ratio of one to four to two) [14]. Spots were located using saturated iodine 
chamber. Effluents with similar profile were combined together, concentrated over a 
water bath and allowed to evaporate to dryness at room temperature. This resulted in 
2 fractions: Vernonia amygdalina saponin fraction A (Va-SA) 0.932 g, eluted with 
chloroform/methanol and Vernonia amygdalina saponin fraction B (Va-SB) 1.35 g, 
eluted with methanol. A preliminary screening of both fractions using foaming test 




Twenty five Wistar rats weighing between 120-200 g (antipyretic study) and 25 
albino mice weighing between 20-25 g (antinociceptive study) of both sexes were 
placed in standard cages where they were maintained on standard animal pellets 
(Nuvita Feeds Ltd., Kampala) and water ad libitum. The rats for antipyretic evaluation 
were selected based on their measured basal anal temperature (≤ 37 0C) using a 
thermistor probe (with a resolution of 0.0005 and accurate to 0.001 oC), and also 
achieving a minimum of 0.1 0C increase in anal temperature in response to 10 ml/kg 
intra-peritoneal (i.p) administered 15% w/v Saccharomyces cerevisiae. The animals for 
the two evaluations (antipyretic and antinociceptive) were randomly divided into five 
groups of five animals each and fasted over night. 
 
National Institute of Health (NIH) guide for the care and use of laboratory animals 
approved by the Institutional Ethical Committee was adopted for the animal protocol 
in this study [15]. 
 
Preparation and Administration of Drug 
All the standards and tests samples were prepared using sterile normal saline solution 
which also, served as placebo in the different experiments. Oral administration was 
carried out using a canula-syringe assemblage. 
 
Antipyretic Study 
Standard procedure as described by previous study was adopted for this study [16]. 
Wistar rats earlier selected and induced pyrexia as described above, were randomly 
divided into five groups of five animals each. The animals were allowed to starve 
overnight in their respective cages. Twenty hours after the administration of 
Saccharomyces cerevisae solution, the anal temperature of each animal in their 
respective group was measured. Oral administration of normal saline to group one, 
ASA to group two and aqueous extracts (400 mg/kg, 600 mg/kg or 800 mg/kg) to 
groups three to five was immediately carried out after the anal temperature 
measurement. Four hours after the administration of the dose, the anal temperature of 
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Similar antipyretic evaluation procedure was adopted for the crude saponin using 
three dose levels: 200, 400 and 600 mg/kg of crude saponin; and for the Va-SB also, 
using 200, 300 and 400 mg/kg of the chromatographic fraction, Va-SB as test doses. 
Doses were based on prior study of crude saponin content in V. amygdalina leaf [17]. 
 
Antinociceptive Study 
WRITHING TEST: Following literature techniques, 0.6% acetic acid solution 
administered by intra peritoneal (i.p) route at a dose of 15 ml/kg was used to induce 
writhing (typical abdominal constriction response consisting of abdominal wall 
contraction, pelvic rotation and hind limb extension) 30 minutes after oral 
administration of acetylsalicylic acid (non-opiate reference standard), morphine 
sulphate (opiate reference standard), normal saline (placebo), V. amygdalina aqueous 
extract (800 mg/kg) or crude saponin (600 mg/kg) to the mice. Each mouse was 
returned to the cage [18]. Five minutes after the administration of acetic acid, writhing 
counts were taken for five minutes under a double blind observation. Antinociceptive 
effects of the standard and test samples were measured by comparing their mean 
abdominal writhes count to the mean writhe count of the placebo group 
 
[(c - t or s)/c] x 100 
 
 where c is mean writhes count for placebo; t or s is mean writhes count for any of the 
tests or standards. 
 
HOT PLATE TEST: Prior to dose administration, the mice were selected on the basis 
of their basal reaction time (fore paw licking or jumping off) when placed on the hot 
plate which was maintained at 55 °C ± 1. Animals with ≤ 8 seconds reaction time 
were regarded as appropriate for inclusion [19]. Sixty minutes after oral 
administration of acetylsalicylic acid, morphine sulphate, normal saline, V. 
amygdalina aqueous extract (800 mg/kg) or crude saponin (600 mg/kg), to the mice in 
the respective groups, the mice were exposed to the hot plate. The Time taken for 
either fore paw licking or jumping off the hot plate was documented as reaction time. 
The group reaction time was taken as mean of the reaction times.  Fifteen seconds was 
taken as cut-off period to avoid damage to paws. Maximum possible analgesia (MPA) 
was calculated as follows [20]. 
 
[(T1-T0) / (15- T0)] x 100 
 
T1 is mean reaction time for standard or test; T0 is mean reaction time for placebo. 
 
COLD TAIL FLICK TEST: The mice were selected for this study based on their 
latent period of tail-flick response. A modified literature procedure was followed [21]. 
Prior to dose administration, two cm length of the animal’s tail was immersed into a 
cold one to one mixture of water and ethylene glycol maintained at -10 °C with an 
ultra low temperature freezer (UF 650 Napcoil, Thermo Electric Corporation). 
Animals with response ≤ 15 seconds were selected. Sixty minutes after oral 
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amygdalina aqueous extract (800 mg/kg) or crude saponin (600 mg/kg), animals were 
similarly exposed to the mixture. The response for each animal was taken as the 
elapsed time for tail deflection from the mixture. Three different reaction time 
readings were taken for each mouse. The first reading was discarded and the mean of 
the last two readings taken as the reaction time. The response for each group was as 
the mean of the reaction times of the five mice. Using 30 seconds as the reaction cut-
off period to avoid damage to the tail, the MPA was calculated as 
 
[(T1-T0) / (30- T0)] x 100 
 
T1 is mean reaction time for standard or test; T0 is mean reaction time for placebo. 
 
Statistical Analysis of Data 
Results and calculations were based on the numerical expression of data as mean ± 
SEM. Analysis of variance (ANOVA) was used to analyse values within groups and 
student T-test, to analyse data between groups. P ≤ 0.05 was taken as level of 





Standard test for phytochemical constituents revealed the presence of saponins, 
alkaloids, sophisticated lactones, triterpenoids, reducing sugars, amino acids, 
flavonoids, terpenoids, tannins and cardiotonic glycosides but absence of quinine. 
 
Antipyretic Study 
The antipyretic study showed a dose dependent response with the extract (table 1), 
crude saponin (table 2) and Va-SB fraction (table 3). Statistical analysis using 
ANOVA indicated no significant (P ≤ 0.05) difference in the yeast induced anal 
temperature within and among groups. T-test analysis indicated significant (P ≤ 0.05) 
dose induced anal temperature decrease for all the test samples in the different 
evaluations. However, at similar dose levels of 400 (figure 1) and 200 mg/kg (figure 













Figure 1: Comparing the relative induced anal temperature decrease of the 
crude saponin and Vernonia amygdalina Saponin fraction B (Va-SB) 




Figure 2: Comparing the relative induced anal temperature decrease of the 
crude saponin and Vernonia amygdalina saponin fraction B (Va-SB) in 
rats at 200 mg/kg dose level 
 
Antinociceptive Study 
Writhing Test: The acetic acid induced writhe count data for standards, aqueous 
extract and crude saponin doses were significantly (P ≤ 0.05) different from that of 
normal saline (placebo). The  antinociception effect was markedly observed with 
morphine sulphate at 89.69% and ASA at 86.60% (table 4). 
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Hot Plate Test: Relative to the placebo (normal saline) group, result obtained with 
this test showed significant (P ≤ 0.05) reaction time for all the standards and test 
samples. Lower data were obtained with the crude saponin at 14.24% MPA (table 5). 
 
Cold Tail Flick Test: Reaction time obtained with the cold tail flick test was 
significant (P ≤ 0.05) for morphine sulphate and the aqueous extract. Acetylsalicylic 




Vernonia amygdalina leaf is used by local communities in Africa and Arabian 
Peninsula. The use of the leaf as food has always required a prior processing leading 
to the loss of possible medicinal principle [22]. In the antipyretic study, brewer’s 
yeast was used as an exogenous stimulus to induce pyrexia; the mode of action may 
be similar to that reported for lipopolyssacharides in laboratory animals [23]. Such 
induction commonly activates the arachidonic acid pathway and has been associated 
with increase in prostaglandin E2 (PGE2) [24]. According to David et al. [25], 
inhibiting the arachidonic acid pathway, and specifically the activity of cyclo-
oxygenase, may result in the reduction of PgE2 level within the hypothalamus [25]. 
Such inhibitory activity ultimately decreases elevated body temperature [25]. The 
antipyretic activity data obtained in the present study indicated that the aqueous 
extract, crude saponin and Va-SB at the doses used significantly (P ≤ 0.05) decreased 
the yeast induced anal temperature in the rats. This suggests that the test samples just 
like the ASA standard possess inhibitory activity against the arachidonic acid 
pathway. 
 
At the same dose levels of 400 and 600 mg/kg, the data indicated higher anal 
temperature decrease (0.55 oC and 0.91 oC) for the leaf extract used in this study, 
compared to the observed 0.32 oC and 0.85 oC obtained with the root extract of the 
plant by Okokon and Onah [16].  
 
Data obtained for crude saponin and its chromatographic fraction, Va-SB at similar 
dose levels (figure 1 and figure 2) suggest the presence of other principle(s) in the 
crude saponin. Such principle(s) like flavonoid compounds which could have been 
lost during the chromatographic process, may have antipyretic or potentiating effect 
as reported by a prior study [26]. However, no test was carried out to determine the 
extent of difference in the phyto-constitution between the crude saponin and Va-SB 
samples. 
 
The antinociceptive study was carried out using the writhing, hot plate and cold tail 
flick test method. This approach was focused on determining and identifying the 
antinociceptive mechanism of the test samples. In the writhing test, intra peritoneal 
administration of 0.6% acetic acid induced pain in form of writhes in the mice. The 
acid produces this effect by stimulating the release of various endogenous pain 
mediators peripherally which excite the nociceptors [27, 28]. Obtained data showed 
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standards, were able to significantly (P ≤ 0.05) decrease the number of writhes 
obtained. This observation suggests the inhibition of the effects of the endogenous 
pain mediators by these test samples. However, writhing test is limited by its lack of 
bias for either central or peripheral activity [28]. 
 
In hot plate test, thermal pain has been demonstrated to be induced in smaller animals 
like mice at 55 °C ± 1. Such pains are known to be initiated via the Aδ fibers through 
the neospinothalamic pathway [27]. In this evaluation, obtained antinociceptive data 
for the aqueous extract were significantly (P ≤ 0.05) different from the placebo. At a 
reaction time of 3.02 seconds relative to the placebo, the extract produced lesser 
activity compared to the opioid standard, morphine sulphate (6.52 seconds).  Marginal 
increase in reaction time which was also significantly (P ≤ 0.05) different from the 
placebo was observed with the crude saponin. However, while findings may suggest 
the inhibition of the neospinothalamic pathway (central activity) by the extract, data 
obtained in this study cannot strongly support the central niociceptive inhibitory 
activity of the crude saponin. The hot plate technique have bias for centrally acting 
antinociceptive agents, but it is also known to lack sufficient sensitivity in 
distinguishing between opiates and non-opiates with central niociceptive inhibition 
[20].  
 
The cold tail flick test has been demonstrated to sufficiently identify opiates from 
non-opiates with central activity [20]. Data in the cold tail flick test showed that the 
aqueous extract produced increased reaction time which was significantly (P ≤ 0.05) 
different from the placebo (normal saline). This observation was similar, although 
lower than data obtained with opioid standard, morphine sulphate. 
 
The findings of the antinociceptive activity test supports previous data on the 
peripheral and central activity of Vernonia amygdalina leaf aqueous extract [28]. 
However, data obtained in this study gave a strong indication that the crude saponin 
constituent could be a major participant in the peripheral antinociceptive activity of 
the aqueous extract. This agrees with an earlier in vivo study with Vernonia cinerea 
that suggests the presence of phytochemicals like saponins to be responsible for the 
observed antinociceptive property [29]. 
 
Generally, saponins are considered to be toxic with majority being powerful 
haemolytics in vitro. However, large doses may be needed to produce toxic effect 
when administered parenterally and larger doses due to poor absorption, when 
administered orally. Several toxicity tests has shown that the lethal oral dose of 
saponins is 3–1000 times as large as the lethal intravenous dose  
[30]. As such, toxicity of saponins to warm blooded animals is dependent on the 
method of administration, source, composition, and concentration of the saponin 
mixture [8]. Data obtained from previous in vivo studies using rats, mice and rabbits 
showed that saponins are not absorbed in the alimentary channel but hydrolyzed to 
their corresponding sapogenins (aglycone) and sugar, by enzymatic action in the 
gastrointestinal tract [5]. The readily more absorbable aglycone is because of this 
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orally administered saponins. This may explain the safety of orally administered 
Vernonia amygdalina extract or products [30]. 
 
 In conclusion, the result obtained in this study indicates that the aqueous extract of 
Vernonia amygdalina leaf possesses antipyretic and antinociceptive activity. The 
crude saponin and Va-SB fraction indicate that saponins are major participants in 
these activities. The Va-SB fraction should be studied further for identifiable pure 
component(s) that may be associated with the observed antipyretic and 
antinociceptive activities.  
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20 hrs after yeast administration the 
anal Temp.0C readings are Dose Induced Anal 
Temp.0C Decrease  0 hrs (after 
Dose admin.) 
4 hrs (after Dose 
admin.) 
1. Placebo 
Normal saline  5 
ml/kg 
39.02 ± 0.11 39.01 ± 0.11 0.02 ± 0.02 
2. Standard ASA 300 mg/kg 39.12 ± 0.10 38.97 ± 0.07 
*0.15 ± 0.04  
(P = 1.65x10-6) 
3. Test 1 Extract 400 mg/kg 39.21 ± 0.18 38.66 ± 0.17 
*0.55 ± 0.03 
(P = 5.3x10-10) 
4. Test 2 Extract 600 mg/kg 39.09 ± 0.20 38.18 ± 0.15 
*0.91 ± 0.09 
(P = 6.8x10-6) 
5. Test 3 Extract 800 mg/kg 39.08 ± 0.13 37.58 ± 0.19 
*1.50 ± 0.20 
(P = 6.7x10-7) 
Data are mean ± SEM (standard error of mean) value (n = 5). *Significantly (P ≤ 









Volume 13 No. 2  
April 2013 




20 hrs after yeast administration, the 
anal Temp.0C readings are Dose Induced Anal 
Temp.0C Decrease  0 hrs (after 
Dose admin.) 
4 hrs (after Dose 
admin.) 
1. Placebo 
Normal saline  
5 ml/kg 
39.054 ± 0.12 39.04 ± 0.11 0.014 ± 0.02 
2. Standard ASA 300 mg/kg 39.10 ± 0.11 38.95 ± 0.08 
*0.15 ± 0.04 




38.75 ± 0.25 38. 62 ± 0.24 
*0.14 ± 0.02 




38.78 ± 0.19 38.49 ± 0.18 
*0.29 ± 0.01 




38.66 ± 0.11 38.29 ± 0.11 
*0.39 ± 0.01 
(P = 1.06x10-5) 
Data are mean ± SEM (standard error of mean) value (n = 5). *Significantly (P ≤ 
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Table 3: Effect of the Vernonia amygdalina chromatographic fraction, Va-SB on 
the anal temperature in rats 4 hrs after Administration 
 
Group Dose 
20 hrs after yeast administration, the 
anal Temp.0C readings are Dose Induced Anal 
Temp.0C Decrease  0 hrs (after Dose 
admin.) 
4 hrs (after Dose 
admin.) 
1. placebo 
Normal saline  5 
ml/kg 
38.01 ± 0.29 37.96 ± 0.28 0.05 ± 0.04 
2. Standard ASA 300 mg/kg 37.84 ± 0.22 37.64 ± 0.23 
*0.19 ± 0.01 
(P = 4.7x10-4) 
3. Test Va-SB 200 mg/kg 37.87 ± 0.27 37.81 ± 0.27 
*0.06 ± 0.01 
(P = 3.1x10-3) 
4. Test  Va-SB 300 mg/kg 37.83 ± 0.28 37.69 ± 0.28 
*0.14 ± 0.01 
(P = 2.2x10-3) 
5. Test  Va-SB 400 mg/kg 37.82 ± 0.25 37.67 ± 0.25 
*0.15 ± 0.01 
(P = 1.45x10-3) 
Data are mean ± SEM (standard error of mean) value (n = 5). *Significantly (P ≤ 
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Table 4: Effect of V. amygdalina leaf aqueous extract and crude saponin in the 
acetic acid induced writhing test in mice 
 




1. Placebo Normal Saline 5 ml/kg 19.4 ± 2.51 0 
2. Opiate 
Standard 
morphine sulphate 5 
mg/kg 
*2 ± 0.71 
(P = 8.7x10-5) 
89.69 
3. Non-opiate 
    Standard 
300 mg/kg acetylsalicylic 
acid 
*2.6 ± 0.55 





*5.6 ± 0.89 





*9.2 ± 0.84 
(P = 1.1x10-3) 
52.58 
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Table 5: Effect of V. amygdalina leaf aqueous extract and crude saponin in the 
thermal stimulus-induced hot plate test in mice 
 
Groups Dose Mean Reaction Time (sec) MPA 
1. Placebo Normal Saline 5 ml/kg 5.49  ± 0.07 0 
2. Opiate Standard morphine sulphate 5 mg/kg 
*9.62 ± 0.12 
(P = 6.2x10-8) 43.39 
3. Non-opiate 
    Standard 
300 mg/kg acetylsalicylic 
acid 
5.51 ± 0.49 
(P = 0.1.9x10-1) 0.21 
4. Aqueous Extract 800 mg/kg 
*7.90 ± 0.74 
(P = 8.4x10-4) 25.3 
5. Crude Saponin 600 mg/kg 
*6.84 ± 0.30 
(P = 2.7x10-4) 14.24 
Data are mean ± SEM value (n = 5). *Significantly (P ≤ 0.05) different from placebo. 
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Table 6: Effect of V. amygdalina leaves’ aqueous extract and crude saponin in 
the thermal stimulus-induced cold tail flick test in mice 
 
Groups Dose Mean Reaction Time (sec) MPA 
1. Placebo Normal Saline 5 ml/kg 19.72 ± 1.11 0 
2. Opiate Standard morphine sulphate 5 mg/kg 
*26.24 ± 1.29 
(P = 1.6x10-4) 
63.42 
3. Non-opiate 
    Standard 
300 mg/kg acetylsalicylic acid 
*20.56 ± 0.77 
(P = 0.008.2x10-3) 
8.17 
4. Aqueous Extract 800 mg/kg 
*22.74 ± 0.90 
(P = 0.003.5x10-3) 
29.38 
5. Crude Saponin 600 mg/kg 
19.04 ± 0.73 
P = 1.4x10-1) 
#-6.62 
Data are mean ± SEM value (n = 5). *Significantly (P ≤ 0.05) different from placebo. 
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